אליגרד 7.5 מ"ג - Eligard 7.5 mg
ש××× ×× !
×ת×ר××: 10/01/2024 ×תק××× ××××¢× ×× ×©××××§ ×תר××¤× ××פסק ×צ××ת×ת.
×ת×ר××: 10/01/2024 ×תק××× ××××¢× ×× ×©××××§ ×תר××¤× ××פסק ×צ××ת×ת.
××§×ר: ××©×¨× ××ר×××ת - ××××¢×ת ×¢× ×פסקת ש××××§ תר×פ×ת
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | L02AE Gonadotropin-releasing hormone analogues | ||||||||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||
| צ×רת ××ª× | תת-×¢××¨× - S.C | ||||||||||||||||||
| צ×רת ××× ×× | ×××§× ×××ס ×××× ×ª ת×××¡× ×××רק×, POWDER AND SOLVENT FOR SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||
| ×ת×××× | ELIGARD is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy. | ||||||||||||||||||
| |||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ×××××¨× 7.5 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | ASTELLAS PHARMA EUROPE B.V, THE NETHERLANDS |
| ×©× ××¢× ×ר×ש×× | KAMADA LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 04/2012. ר×ש××× ×ת×ר××: 08/2016 |
| ת×ר×× ×¢×××× ××ר×× | 10/01/2024 |
השינוי האחרון נעשה בֹ־4 בדצמבר 2016 ב־22:58